Trends in Cardiovascular Medicine最新文献_第8页

ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases ANGPTL3 抑制、血脂异常和心血管疾病。

IF 9.3 2区医学

Trends in Cardiovascular Medicine Pub Date : 2024-05-01 DOI: 10.1016/j.tcm.2023.01.008

Fei Luo , Avash Das , Sumeet A. Khetarpal , Zhenfei Fang , Thomas A Zelniker , Robert S. Rosenson , Arman Qamar

{"title":"ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases","authors":"Fei Luo , Avash Das , Sumeet A. Khetarpal , Zhenfei Fang , Thomas A Zelniker , Robert S. Rosenson , Arman Qamar","doi":"10.1016/j.tcm.2023.01.008","DOIUrl":"10.1016/j.tcm.2023.01.008","url":null,"abstract":"<div>Optimal management of low-density lipoprotein cholesterol (LDL-C) is a central tenet in the primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD). However, significant residual cardiovascular risk remains despite achieving guideline-directed LDL-C levels, in part due to mixed hyperlipidemia with elevated fasting and non-fasting triglyceride-rich lipoprotein levels. Advances in human genetics have identified angiopoietin-like 3 (ANGPTL3) as a promising therapeutic target to lower cardiovascular risk. Evidence accrued from genetic epidemiological studies demonstrate that ANGPTL3 loss of function is strongly associated with lowering of circulating LDL-C, triglyceride-rich lipoproteins and concurrent risk reduction in development of coronary artery disease. Pharmacological inhibition of ANGPTL3 with monoclonal antibodies, antisense oligonucleotides and gene editing are in development with early studies showing their safety and efficacy in lowering in both, LDL-C and TGs, circumventing a key limitation of previous therapies. Monoclonal antibodies targeting ANGPTL3 are approved for clinical use in homozygous familial hypercholesteremia in USA and Europe. Although promising, future studies focusing on long-term beneficial effect in reducing cardiovascular events with inhibition of ANGPTL3 are warranted.</div>","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":"34 4","pages":"Pages 215-222"},"PeriodicalIF":9.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9371308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Atrial fibrillation and the risk of early-onset dementia and cognitive decline: An updated review 心房颤动与早发性痴呆和认知能力下降的风险：最新综述。

IF 9.3 2区医学

Trends in Cardiovascular Medicine Pub Date : 2024-05-01 DOI: 10.1016/j.tcm.2023.01.005

Benjamin Kogelschatz, Brian Zenger, Benjamin A. Steinberg, Ravi Ranjan, T. Jared Bunch

引用次数: 0

Editorial commentary: Left atrial appendage occlusion for prevention of thromboembolism in atrial fibrillation: Is it ready for first line therapy? 用于预防心房颤动血栓栓塞的左心房阑尾封堵术：是否可以作为一线疗法？

IF 9.3 2区医学

Trends in Cardiovascular Medicine Pub Date : 2024-05-01 DOI: 10.1016/j.tcm.2023.02.007

Deepak Bhakta , Marina Sharif

引用次数: 0

Editorial commentary: Is seeing really believing? The role of the 12 lead electrocardiogram in cardiac amyloidosis 社论评论：眼见为实吗？12 导联心电图在心脏淀粉样变性中的作用

IF 9.3 2区医学

Trends in Cardiovascular Medicine Pub Date : 2024-05-01 DOI: 10.1016/j.tcm.2023.03.001

Jasneet Devgun , Karthikeyan Ananthasubramaniam

引用次数: 0

Editorial commentary: Predicting post-operative atrial fibrillation (POAF): The proof is in the fluid 编辑评论：预测术后心房颤动 (POAF)：证据就在液体中

IF 9.3 2区医学

Trends in Cardiovascular Medicine Pub Date : 2024-05-01 DOI: 10.1016/j.tcm.2023.07.005

Joshua A. Newman , Peter R. Kowey

引用次数: 0

The role of pericardial fluid biomarkers in predicting post-operative atrial fibrillation, a comprehensive review of current literature 心包积液生物标志物在预测术后心房颤动中的作用，当前文献综述。

IF 9.3 2区医学

Trends in Cardiovascular Medicine Pub Date : 2024-05-01 DOI: 10.1016/j.tcm.2023.02.009

Kiera Liblik , James Zucker , Adrian Baranchuk , Angel Luis Fernandez , Shetuan Zhang , Mohammad El Diasty

{"title":"The role of pericardial fluid biomarkers in predicting post-operative atrial fibrillation, a comprehensive review of current literature","authors":"Kiera Liblik , James Zucker , Adrian Baranchuk , Angel Luis Fernandez , Shetuan Zhang , Mohammad El Diasty","doi":"10.1016/j.tcm.2023.02.009","DOIUrl":"10.1016/j.tcm.2023.02.009","url":null,"abstract":"<div>Post-operative atrial fibrillation (POAF) is a common complication of cardiac surgery which is associated with longer hospital stay, diminished quality of life, and increased mortality. Yet, the pathophysiology of POAF is poorly understood and it is unclear which patients are at highest risk. Pericardial fluid (PCF) analysis is emerging as an important tool for the early detection of biochemical and molecular changes in the cardiac tissue. With the epicardium acting as a semi-permeable membrane, the composition of PCF reflects the activity of the cardiac interstitium. Emerging research on PCF composition has identified promising biomarkers which may help stratify the risk for developing POAF. These include inflammatory molecules, such as interleukin-6, mitochondrial deoxyribonucleic acid, and myeloperoxidase, as well as natriuretic peptides. Additionally, PCF appears to be superior to serum analysis in detecting changes in these molecules during the early postoperative period after cardiac surgery. The aim of the present narrative review is to summarize the current literature on the temporal changes in the levels of potential biomarkers in PCF after cardiac surgery and their association with the development of new-onset postoperative atrial fibrillation.</div>","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":"34 4","pages":"Pages 244-247"},"PeriodicalIF":9.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10859871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial commentary: Atrial fibrillation and dementia: Time to reconsider the therapy outcomes relevant for patients? 心房颤动与痴呆症：是时候重新考虑与患者相关的治疗结果了吗？

IF 9.3 2区医学

Trends in Cardiovascular Medicine Pub Date : 2024-05-01 DOI: 10.1016/j.tcm.2023.02.005

Evgeny Lyan , Thomas Demming , Derk Frank

引用次数: 0

Head-to-head comparison between left atrial appendage occlusion and non-vitamin K oral anticoagulants in non-valvular atrial fibrillation patients: A systematic review and meta-analysis study 非瓣膜性心房颤动患者左心房阑尾封堵术与非维生素 K 口服抗凝剂的正面比较：系统回顾和荟萃分析研究。

IF 9.3 2区医学

Trends in Cardiovascular Medicine Pub Date : 2024-05-01 DOI: 10.1016/j.tcm.2023.02.002

Yoga Waranugraha , Lian-Yu Lin , Chia-Ti Tsai

{"title":"Head-to-head comparison between left atrial appendage occlusion and non-vitamin K oral anticoagulants in non-valvular atrial fibrillation patients: A systematic review and meta-analysis study","authors":"Yoga Waranugraha , Lian-Yu Lin , Chia-Ti Tsai","doi":"10.1016/j.tcm.2023.02.002","DOIUrl":"10.1016/j.tcm.2023.02.002","url":null,"abstract":"<div>Left atrial appendage occlusion (LAAO) was found to be non-inferior to warfarin. In non-valvular atrial fibrillation (AF), there is still a scarcity of data comparing LAAO versus non-vitamin K oral anticoagulants (NOACs). Our purpose was to compare the clinical benefits between LAAO and NOACs in non-valvular AF patients. The patient, intervention, comparison, and outcome principles were used to develop the research question in this systematic review and meta-analysis. Literature searches were conducted in online scientific databases such as ProQuest, PubMed, and ScienceDirect. All important information was extracted. The random-effect model was applied to estimate all pooled effects. The Mantel-Haenszel statistical method was used to determine the pooled risk ratio (RR) and 95% confidence interval (CI). A total of 4411 participants from 5 studies were involved. LAAO significantly decreased the cardiovascular mortality risk compared to NOACs (RR = 0.56; 95% CI = 0.42 to 0.75; p <0.01). Major bleeding risk in the LAAO group was significantly lower than in the NOACs group (RR = 0.66; RR = 0.53 to 0.82; p <0.01). A significantly lower risk of major bleeding or non-major bleeding in the patients receiving LAAO than NOACs was also observed in this meta-analysis (RR = 0.66; 95% CI = 0.54 to 0.81; p <0.01). LAAO was superior to the NOACs in reducing cardiovascular mortality, major bleeding, and major or non-major bleeding risks in non-valvular AF patients. In high-risk thromboembolism and bleeding patients, LAAO can be considered first as a long-term treatment strategy.</div>","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":"34 4","pages":"Pages 225-233"},"PeriodicalIF":9.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10759850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oral health as a modifiable risk factor for cardiovascular diseases 口腔健康是心血管疾病的一个可改变的风险因素。

IF 9.3 2区医学

Trends in Cardiovascular Medicine Pub Date : 2024-05-01 DOI: 10.1016/j.tcm.2023.03.003

Serena Altamura , Rita Del Pinto , Davide Pietropaoli , Claudio Ferri

引用次数: 0

Editorial commentary: Genetics keeps on giving: A possible vaccine for heart disease 遗传学一直在进步：可能的心脏病疫苗

IF 9.3 2区医学

Trends in Cardiovascular Medicine Pub Date : 2024-05-01 DOI: 10.1016/j.tcm.2023.02.008

Robert Roberts

引用次数: 0